RespireRx Pharmaceuticals Inc (RSPI)

[tonyvanw]

<My problem this past week was Wal-Marts 4 dollar ad/adhd generics.>

Worrying about the Walmart $4 generic appears to me to be overkill. There must be better things to worry about. First of all, a marketable product is still years in the future and secondly, CX717's advantages (non-stimulant, non-addictive, lack of side effects) are such that they will create its own market. What would be your choice of product for your personal usage, if needed?

<And then the feeling that should the IND be approved, which while I felt that was likely, I also felt the upside from that event would not be much, just like the bump from CX717 being released from hold was only about half as much as most on the board were thinking.>

I tend to agree with you, I also do not expect much of an effect on the share price, although I would welcome being wrong in my expectation.

In spite of my low expectation of price appreciation on the IND approval, the share price seems very cheap and I have been adding shares (and adding to my cumulative loss).